| Identification | Back Directory | [Name]
XL-647 | [CAS]
781613-23-8 | [Synonyms]
XL-647
Tesevatinib
Tesevatinib(XL647)
N-(3,4-dichloro-2-fluorophenyl)-6-Methoxy-7-(((3aR,6aS)-2-Methyloctahydrocyclopenta[c]pyrrol-5-yl)Methoxy)quinazolin-4-aMine
N-(3,4-Dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aalpha,5beta,6aalpha)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-4-quinazolinamine | [Molecular Formula]
C24H25Cl2FN4O2 | [MDL Number]
MFCD23726660 | [MOL File]
781613-23-8.mol | [Molecular Weight]
491.385 |
| Chemical Properties | Back Directory | [Boiling point ]
567.9±50.0 °C(Predicted) | [density ]
1.356 | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10 mg/ml; DMSO: 10 mg/ml; Ethanol: 10 mg/ml | [form ]
A solid | [pka]
10.16±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
XL 647 is a potent and selective EGFR phosphorylation inhibitor and may be used in the treatment of patients suffering from lung cancer. Orally available, multi-target tyrosine kinase inhibitor. | [Definition]
ChEBI: Tesevatinib is a member of the class of quinazolines that is quinazoline substituted by (3,4-dichloro-2-fluorophenyl)amino, methoxy, and [(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy groups at positions 4, 6 and 7, respectively. It is a multi-target tyrosine kinase inhibitor of EGFR, ErbB2, KDR, Flt4 and EphB4 and exhibits anti-cancer properties. It has a role as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an epidermal growth factor receptor antagonist. It is a member of quinazolines, an aromatic ether, a member of monofluorobenzenes, a dichlorobenzene, a secondary amino compound, a diether and a tertiary amino compound. |
|
|